Study opens eyes to Alzheimer’s disease risk
Not only a window to our souls, the eyes may also provide doctors of optometry an opening to patients' risks for Alzheimer's disease, a new study says.
The study, by University of Washington (UW) researchers, involved 3,877 adults age 65 and older, who were part of an ongoing, prospective cohort study initiated in 1994 ("Adult Changes in Thought"). From the outset, dementia-free, study participants were assessed for poor vision and cognition, researchers say, but they were followed over time until they developed dementia, dropped out or died. Alzheimer's, a chronic, progressive neurodegenerative disease, is a leading cause of dementia
In the study, published Aug. 8 in Alzheimer's & Dementia, the journal of the Alzheimer's Association, researchers looked at Alzheimer's risk for glaucoma, age-related macular degeneration (AMD), diabetic retinopathy and cataracts.
They found that glaucoma, AMD and diabetic retinopathy were associated with increased risk for Alzheimer's, controlling for several factors including age, sex, education and smoking. Not so for cataracts.
"There was no association between cataract and Alzheimer's disease," the researchers say. "Without a temporal window, 20% higher Alzheimer's disease risk was found in participants with AMD and 44% higher Alzheimer's disease risk in those with diabetic retinopathy compared with those without.
"When we separated recent versus established ophthalmic conditions, we found a 46% higher Alzheimer's disease risk in participants with recent glaucoma compared with those without, but no increased risk for those with established glaucoma," they say. "In comparison with those without AMD, Alzheimer's disease risk in participants with recent and established AMD were 20% and 50% higher; only the latter was statistically different from the null. Participants with recent and established diabetic retinopathy were at a higher Alzheimer's disease risk by 67% and 50% compared with those without."
It would be tempting to dismiss the findings as "age-related phenomena," they add. Researchers conjectured in the study that the findings were due to more than that, the potential impact of their neurodegenerative pathways.
Key takeaway for doctors of optometry
Leo Semes, O.D., professor emeritus at the University of Alabama-Birmingham School of Optometry, praises the study for its large cohort, long-term follow-up of patients and well-defined criteria at baseline.
The study also underscores and extends for doctors of optometry the understanding of the risk factors for Alzheimer's disease, especially as it manifests in the eyes. The sooner doctors can detect and undertake sight-preserving treatment, the better, he says.
"There seems to be a growing body of evidence that these neurodegenerative disorders—whether it's glaucoma, Alzheimer's, ALS (amyotrophic lateral sclerosis), Parkinson's—might show up very early in the eyes," Dr. Semes says, taking additional note of the higher risk for patients with more recent diagnoses in some conditions.
"The earlier a diagnosis is made the more likely interventions will be valuable," he says, noting the growing prevalence of diabetes and the slow-creeping symptoms of glaucoma. "What they are trying to establish is some common pathways that might make it easier to recognize these conditions before a patient becomes over-symptomatic."
AOA series addresses concerns about myopia management
With the prevalence of myopia on the rise worldwide, an AOA webinar attempts to erase concern over barriers to providing myopia management. The webinar kicked off a three-event series focused on raising awareness of myopia management as a standard of care especially for children. Next is “Meet the Myopia Experts” on Saturday, June 24, at Optometry’s Meeting® 2023 in Washington, D.C.
AOA serving patients through research in optometry
For the fifth consecutive year, the AOA is sponsoring the Investigator Initiated Research Award. Investigators are invited to electronically submit proposals by July 1 for projects designed to increase knowledge through basic clinical and/or translational science relative to the continuum of eye and vision care. The AOA provides a maximum of $50,000 in direct costs for research conduct. Eric Ritchey, O.D., Ph.D., talks about his current research on low-level light therapy for patients with meibomian gland dysfunction, which can lead to dry eye disease.
Marijuana sensibilities changing fast: Are you ready for patients’ questions?
Public support for marijuana legalization has never been higher in the U.S., but evidence of its clinical utility in glaucoma care remains clouded at best.